Otros idiomas Genmab A/S Deutsche Boerse AG

Acciones

GE9

DK0010272202

Tiempo real estimado Tradegate Otros sitios de cotización 19:23:24 03/07/2024			Varia. Cinco días.	Varia. 1 de enero.
233,4 ^EUR	+1,39 %		-4,22 %	-20,15 %

02/07	Ambu A/S: Un líder innovador en equipos médicos de un solo uso
28/06	Se recomienda la aprobación en la UE de una terapia contra el linfoma de Genmab y AbbVie	MT

Otros idiomas

Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!

Inscripción 100% Gratuita

Genmab A/S - Epcoritamab Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed, Refractory Follicular Lymphoma	01/07
Genmab A/S - Completion of Share Buy-back Program	28/06
Would you like some more inflation?	28/06
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	28/06
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	28/06
En Direct des Marchés : Renault, L'Oréal, Schneider Electric, Atos, Nokia, Meta Platforms...	28/06
Vous reprendrez bien un peu d'inflation ?	28/06
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	28/06
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	28/06
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	28/06
Genmab Closes DKK3.5 Billion Share Buyback Early	28/06
Completion of Share Buy-back Program	27/06
Genmab A/S - EPKINLY Approved by U.S. FDA for Patients with Relapsed or Refractory Follicular Lymphoma	27/06
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27/06
Genmab Gets FDA Approval for Follicular Lymphoma Treatment	27/06
Genmab Wins US Approval for Follicular Lymphoma Treatment	27/06
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)	27/06
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)	27/06
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY	27/06
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27/06

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Titulares

GENMAB : Un buen comienzo para 2024; orientación sin cambios

03 de mayo 2024 a las 19:08

Genmab A/S: El otro éxito sanitario danés

13 de junio 2023 a las 16:17